Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims largely align on mechanism and antihypertensive indication, and key pharmacology is supported. However, several safety- and administration-related aspects are not addressed, and multiple generation/patent-related statements are unsupported by the provided label. Overall alignment is partial with notable omissions in safety and dosing administration information.
Category Scores
Accurate Statements
Olmesartan is a medication used to treat high blood pressure.
Indication information in 1 Indications and Usage (hypertension).
Olmesartan works by blocking the action of angiotensin II, a hormone that constricts blood vessels.
12.1 Mechanism of Action.
By inhibiting angiotensin II's effects, olmesartan causes blood vessels to relax and widen, thereby lowering blood pressure.
12.1 Mechanism of Action.
Lowering blood pressure reduces the risk of serious cardiovascular events such as heart attack and stroke.
1 Indications and Usage; cardiovascular risk discussion in label text.
Olmesartan-medoxomil-induced enteritis can cause severe diarrhea.
5.8 Warnings and Precautions: Sprue-like enteropathy (OAE).
Olmesartan-medoxomil-induced enteritis can cause substantial weight loss.
5.8 Warnings and Precautions: Sprue-like enteropathy (OAE).
The choice of medication depends on individual patient factors and medical history.
1 Indications and Usage.
Olmesartan medoxomil and hydrochlorothiazide combination dosing information (e.g., 20/12.5 mg, 40/12.5 mg, 40/25 mg) is described in the clinical studies section.
14 Clinical Studies; Table 2 and accompanying text.
Olmesartan works by blocking the action of angiotensin II, a hormone that constricts blood vessels (MOA).
12.1 Mechanism of Action.
By inhibiting angiotensin II's effects, olmesartan causes blood vessels to relax and widen, thereby lowering blood pressure (MOA).
12.1 Mechanism of Action.
Unsupported Statements
Patents related to olmesartan and its formulations can vary in expiry dates.
Patent status and expiry information are not described in the FDA labeling provided.
Companies often hold multiple patents covering different aspects of olmesartan, including its active ingredient, manufacturing processes, and specific uses.
Patent landscape is not discussed in the FDA labeling provided.
DrugPatentWatch.com tracks olmesartan patent expiries.
Not addressed in the FDA labeling provided.
Generic versions of olmesartan can typically enter the market after the expiration of relevant patents, provided they meet regulatory approval standards.
Not addressed in the FDA labeling provided.
The process involves demonstrating bioequivalence to the branded drug.
Bioequivalence/generic development process is not described in the FDA labeling provided.
The availability of generics often leads to a decrease in drug pricing.
Pricing and generic market dynamics are not described in the FDA labeling provided.
Other ARBs include losartan and valsartan.
Class-wide examples are not described in the FDA labeling provided.
ACE inhibitors, calcium channel blockers, diuretics, and beta-blockers are other classes of medications for hypertension.
Pharmacologic class overview outside of olmesartan labeling is not described in the FDA labeling provided.
The original branded version of olmesartan is marketed as Benicar by Daiichi Sankyo.
Branding/history details are not addressed in the FDA labeling provided.
Following patent expirations, various pharmaceutical companies have developed and marketed generic versions of olmesartan.
Not addressed in the FDA labeling provided.
Patent information is critical for understanding the market exclusivity of olmesartan.
Patent information is not discussed in the FDA labeling provided.
Patent information dictates the timeline for generic competition, which directly impacts drug pricing and patient access.
Not addressed in the FDA labeling provided.
Olmesartan belongs to the ARB class of drugs.
Class designation as ARB is not explicitly stated in the provided labeling excerpt.
ACE inhibitors, calcium channel blockers, diuretics, and beta-blockers are other classes of medications for hypertension.
Not addressed in the FDA labeling provided.
The original branded version of olmesartan is Benicar by Daiichi Sankyo.
Branding/historical note not in label excerpt.
Following patent expirations, various pharmaceutical companies have developed and marketed generic versions of olmesartan.
Not addressed in the FDA labeling provided.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Pregnancy risk and boxed warning (8.1) are not addressed.
Importance:
Moderate
Contraindications are not addressed in the evaluated claims.
Importance:
Moderate
Pediatric use and dosing information (8.4 Pediatric Use; 2 Dosing and Administration) are not addressed.
Importance:
Moderate
Detailed dosing and administration instructions for monotherapy and combination therapy are not comprehensively covered.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims largely align on mechanism and indication with limited safety claims presented; however, key safety cautions (pregnancy, contraindications, pediatric use) are not addressed, which modestly increases risk of unsafe/incomplete interpretation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing critical safety information (pregnancy/boxed warnings, contraindications, pediatric use) and incomplete dosing/administration details for comprehensive alignment.
Suggested Improvement
Augment claims with explicit Contraindications, Boxed Warning information (pregnancy), Pediatric Use data, and detailed Dosing and Administration guidance; restrict or remove generation/patent-related content unless sourced from labeling.